SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

This phase II trial studies the side effects and how well vaccine therapy works when given together with temozolomide in treating patients with newly diagnosed glioblastoma. Vaccines made from the survivin peptide or antigen may help the body build an effective immune response to kill tumor cells that express survivin. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether temozolomide is more effective with or without vaccine therapy in treating glioblastoma.

NCT Number	NCT02455557
Lead Sponsor	Roswell Park Cancer Institute
Conditions	Glioblastoma, Gliosarcoma
Enrollment	66 participants
Start Date	2015-05-04
Primary Completion	2019-10-23 (estimated)
Study Completion	2026-09-02 (estimated)
Updated on ClinicalTrials.gov	2026-08-07